Privacy masthead desktop

Privacy Policy

Effective: May 1, 2020

Your privacy is important to us at STAAR Surgical Company ("STAAR"). This privacy statement ("Statement") applies to STAAR Web sites, any mobile applications ("Apps") and digital platforms and services ("Services") (collectively, "Sites") and explains how we collect, use, disclose and otherwise process information that identifies you or from which you are identifiable (“Personal Information”). Please be sure to read this entire Statement before using or submitting information to our Sites.

Personal Information Collected We collect information from you in various ways when you use our Sites. We may collect Personal Information you directly provide on our Sites. In addition, we may collect Personal Information you generate as a user of our Sites or if you are a patient, which you provide to a healthcare professional or an institutional healthcare provider (collectively, "Providers"). Personal Information we may collect includes name, email address, phone number, gender, date of birth and zip code.

Where we collect and process Personal Information about your health or medical status (i.e., “Sensitive Personal Information”) this information may be subject to stricter requirements than other Personal Information. Before providing (or consenting to the disclosure of) Sensitive Personal Information to us, we urge you to carefully consider whether to disclose such information.

In addition, some information may be automatically collected when you visit our Sites – please see Section on Cookies below.

If you are a Provider, you are responsible for providing adequate notice to, and obtaining any legally required authorization, consent or other permission from, your patients prior to providing their Personal Information to STAAR through the Sites (though STAAR does not request patient Personal Information). By submitting any Personal Information about a patient to STAAR, you represent and warrant to STAAR that you have provided adequate notice to and obtained all required consents from patients to do so.

Interactive Services

If you choose to participate in our questionnaires and surveys and other interactive Services, we will collect Personal Information that you disclose, to help us better understand how STAAR products are used in addressing visual conditions for which they are marketed.

The information you provide through interactive Services may be combined (subject to all applicable laws) with the Personal Information provided elsewhere in or through the Services. We may combine your and others' Personal Information to create summary data that we will use for our business purposes, such as research to improve our products and analyses that may help us better market our products.

If you submit Sensitive Personal Information (e.g., health-related information) through the Services to participate in a clinical trial, sweepstake or otherwise, we may use such Sensitive Personal Information to assess whether you qualify for enrollment or participation, to contact you about potential participation, and to provide you with additional information.

You may provide information to be published or displayed ("Posted") on public areas of the Services (collectively, "User Contribution"). If you post User Contributions then you do so at your own risk. STAAR does not control the actions of third parties with access to your User Contributions.

Cookies We may automatically collect certain information through the use of "cookies." Cookies are small data files that are stored on your hard drive by a Web site, which the site may then use to identify you on your next visit. Among other things, the use of cookies helps us to improve our Sites and your experience. We use cookies to see which areas and features are most popular, to count the number of computers accessing our Sites, to personalize your experience, and to remember your preferences.

A "web beacon" is a piece of code that enables us to monitor user activity and website traffic. A "cookie" is a randomly-generated unique numeric code stored in the user's web browser settings or computer's hard drive. A cookie typically contains the name of the domain (internet location) from which the cookie originated, the "lifetime" of the cookie (i.e., when it expires), as well as the randomly generated unique numeric code.

We link the information we store in cookies to any personally identifiable information you submit while on our Sites. If you prefer not to receive cookies on this website, you can set your browser (such as internet explorer, Google Chrome, Mozilla Firefox, etc.) to warn you before accepting cookies and refuse the cookie when your browser alerts you to its presence. You can set your browser not to accept cookies, but if you do so or if you reject a cookie, you may not be able to access some of the features or services of our Sites. We may track your activities over time and across third-party websites, apps or other online services to display advertisements on third-party websites. If you do not want us to use your information in this way, please see "Your Privacy Choices" below. For more information about our digital advertising practices, please see "Digital Advertising" below.

If our third party vendors, consultants and other service providers ("Service Providers") use cookies, their use is not covered by this privacy statement. We do not have access or control over those cookies. Our Service Providers use session ID cookies to collect data in order to enable us to provide a better user experience.

Google, as a third party vendor, uses cookies to serve ads. Google's use of the first party cookies (such as Google Analytics cookies) and third-party cookies (such as the DoubleClick cookie) enables it to serve ads to you based on your visit to our Sites and other sites on the Internet. Additionally, these cookies are used to generate a report on how our ad impressions, other uses of ad services, and interactions with these ad impressions and ad services are related to visits to our Sites. Users may opt out of the use of the cookie by visiting the Google ad and content network privacy Statement here: adssettings.google.com or http://optout.networkadvertising.org/#!/.

Facebook Pixel. We use Facebook Pixel on our Discover ICL site to track visits to the site and to analyze the content a Facebook user has viewed when visiting the Discover ICL site (e.g., EVO Visian ICL videos) in order to measure, optimize and improve the content of the site. This Pixel records information about a Facebook user's session on the Discover ICL website, which it sends to Facebook, along with an anonymised version of the user’s Facebook ID. We collect and store information gathered from the session Facebook Pixel cookie for 180 days. You can delete the Facebook Pixel cookie and other cookies at any time by clearing your browser cache. For further information about the Facebook Pixel please see: https://en-gb.facebook.com/business/help/651294705016616.

Facebook Lead Ad: We use the Facebook Lead Ad to collect users’ full name, email address, city, and postal zip code. STAAR uses this data to contact the user via e-mail to send contact information about Visian ICL certified clinic(s). The user’s data will not be transmitted to the clinics in this process.

Connecting with Social Media through the Services

Certain Services may link with social media platforms and social media plug-ins (e.g., the Facebook "Like" button, "Share to Twitter" button) (collectively, "Social Media"). When accessing the Services through a Facebook or other Social Media account, STAAR may (depending on the applicable user privacy settings) automatically have access to information provided to or through the Social Media platform. STAAR may collect and use this information for the purposes described in this Privacy Statement or at the time the information was collected.

Connecting with Social Media through Service Providers

Third parties that assist us with our business operations also collect and use information (including Personal Information and "Usage Data" (i.e., information about an individual's activity on or through the Services that, by itself, does not identify the individual, such as browser type, operating system and webpages visited)) through the Services and also may share the collected information with us. For example, our vendors collect and share information with us to analyze use of the Services, to help us detect and prevent fraud and to improve user experience.

이보 ICL로 시력의 자유를 되찾을 준비가 되셨나요? 지금 내 주변에 상담 가능한 안과를 찾아보세요.

주요 안전성 정보

이보 ICL은 -0.5 디옵터 ~ -18.0 디옵터의 근시를 효과적으로 교정하고, 이보 Toric ICL은 -0.5 디옵터 ~ -18.0 디옵터의 근시를 교정함과 동시에 0.5 디옵터 ~ 6.0 디옵터의 난시를 교정합니다.

이 범위의 근시가 있는 경우, 이보 ICL 렌즈삽입술은 안경이나 콘택트 렌즈 없이 원거리 시력을 향상시킬 수 있습니다. 이보 ICL 렌즈삽입술은 원거리 시력을 교정하기 때문에 돋보기의 필요성이 없어지는 것은 아닙니다. 돋보기를 이전에 사용한 적이 없더라도 언젠가 필요해질 수 있습니다.

이보 ICL 렌즈삽입술은 외과적 절차이므로 잠재적으로 심각한 위험이 따를 수 있습니다. 안과 전문의와 잠재적 위험에 대해 상담하십시오. 드물기는 하지만 합병증에는 추가 수술, 염증, 각막 뒷면의 세포 손실, 안압 상승, 백내장이 포함될 수 있습니다.

다음과 같은 경우 이보 ICL 렌즈삽입술을 받지 않아야 합니다.

  • 안과 의사가 귀하의 눈 모양이 이보 ICL 렌즈삽입술에 적합하지 않다고 결정한 경우
  • 귀하가 임신 중이거나 수유 중인 경우
  • 렌즈삽입술 당시, 안과 의사가 귀하 연령대의 최소 내피세포밀도를 충족하지 않는다고 결정한 경우
  • 안과 의사가 귀하의 시력이 안정적이지 않다고 결정한 경우

이보 ICL 렌즈삽입술을 고려하기 전 눈 검사를 받고 이보 ICL 렌즈삽입술, 특히 잠재적인 장점, 위험 및 합병증에 대해 안과 전문의와 상담해야 합니다. 수술 후 회복에 필요한 시간을 상의해야 합니다. 잠재적인 장점, 위험 및 합병증에 대한 추가 정보는 홈페이지를 참조하십시오.

참고문헌

참고자료

Home - 광고심의필: 조합-2022-04-030 (유효기간: 2025.02.07)

1. Gonzalo Carracedo, et al. The role of dinucleoside polyphosphates on the ocular surface and other eye structures. Prog Retin Eye Res. 2016 Nov;55:182-205. 2. Paul J Dougherty, et al. Refractive outcomes and safety of the implantable collamer lens in young low-to-moderate myopes. Clin Ophthalmol. 2017;11:273–277. 3. Gregory D. Parkhurst, et al. Phakic Intraocular Lens Implantation in United States Military Warfighters: A Retrospective Analysis of Early Clinical Outcomes of the EVO ICL. J Refract Surg. 2011;27(7);473-481. 4. Feingold et al. Biocompatible, optically transparent, ultraviolet light absorbing, polymeric material based upon collagen and method of making. USPTO June 8, 1999. 5. ICL in Treatment of Myopia (ITM) Study Group. Postoperative Inflammation after Implantation of the Implantable Contact Lens. Ophthalmology 2003;110:2335-2341. 6. Steven Schallhorn, MD et al. Night Driving Simulation in a Randomized Prospective Comparison of Visian Toric Implantable Collamer Lenses and Conventional PRK for Moderate to High Myopic Astigmatism. Journal of Refractive Surgery Vol.26, No. 5, 2010:321-326 7. Gregory D Parkhurst. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clinical Ophthalmology 2016;10:1209-1215. 8. Donald R Sanders et al. United States Food and Drug Administration Clinical Trial of the Implantable Collamer Lens (ICL) for Moderate to High Myopia Three-Year Follow-up. Ophthalmology. 2004;111:1683–1692. 9. Elena Martines-plaze, et al. Effect of the EVO + Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life. Am J Ophthalmol. 2021;226:117-125. 10. Data on file. STAAR Surgical Annual Report.

이보 ICL이란? - 광고심의필: 조합-2022-04-031 (유효기간: 2025.02.07)

1. Feingold et al. Biocompatible, optically transparent, ultraviolet light absorbing, polymeric material based upon collagen and method of making. USPTO June 8, 1999. 2. ICL in Treatment of Myopia (ITM) Study Group. Postoperative Inflammation after Implantation of the Implantable Contact Lens. Ophthalmology 2003;110:2335-2341. 3. Risto J. Uusitalo, et al. Implantable contact lens for high myopia. J Cataract Refract Surg 2002(28):29-36. 4. Gregory D. Parkhurst, et al. Phakic Intraocular Lens Implantation in United States Military Warfighters: A Retrospective Analysis of Early Clinical Outcomes of the EVO ICL. J Refract Surg. 2011;27(7);473-481. 5. FDA. Before, During & After Surgery. https://www.fda.gov/medical-de... (as of 2021-12-24) 6. 윤재문 외. 난시교정용 후방 유수정체 안내렌즈 삽입술의 단기간 임상성적. 대한안과학회지. 2009;50(6):839-851. 7. Steven Schallhorn, MD et al. Night Driving Simulation in a Randomized Prospective Comparison of Visian Toric Implantable Collamer Lenses and Conventional PRK for Moderate to High Myopic Astigmatism. Journal of Refractive Surgery Vol.26, No. 5, 2010:321-326. 8. Gregory D Parkhurst. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clinical Ophthalmology 2016;10:1209-1215. 9. Donald R Sanders et al. United States Food and Drug Administration Clinical Trial of the Implantable Collamer Lens (ICL) for Moderate to High Myopia Three-Year Follow-up. Ophthalmology. 2004;111:1683–1692.

이보 ICL의 장점(야간시력 개선) - 광고심의필: 조합-2022-04-032 (유효기간: 2025.02.07)

1. Steven Schallhorn, MD et al. Night Driving Simulation in a Randomized Prospective Comparison of Visian Toric Implantable Collamer Lenses and Conventional PRK for Moderate to High Myopic Astigmatism. Journal of Refractive Surgery Vol.26, No. 5, 2010:321-326. 2. Gregory D Parkhurst. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clinical Ophthalmology 2016;10:1209-1215. 3. Donald R Sanders et al. United States Food and Drug Administration Clinical Trial of the Implantable Collamer Lens (ICL) for Moderate to High Myopia Three-Year Follow-up. Ophthalmology. 2004;111:1683–1692. 4. FDA. Before, During & After Surgery. https://www.fda.gov/medical-de... (as of 2021-12-24) 5. 윤재문 외. 난시교정용 후방 유수정체 안내렌즈 삽입술의 단기간 임상성적. 대한안과학회지. 2009;50(6):839-851.

이보 ICL의 장점(안구건조증이 걱정되세요?) - 광고심의필: 조합-2022-04-033 (유효기간: 2025.02.08)

1. Gregory D. Parkhurst, et al. Phakic Intraocular Lens Implantation in United States Military Warfighters: A Retrospective Analysis of Early Clinical Outcomes of the EVO ICL. J Refract Surg. 2011;27(7);473-481. 2. FDA. Before, During & After Surgery. https://www.fda.gov/medical-de... (as of 2021-12-24). 3. 윤재문 외. 난시교정용 후방 유수정체 안내렌즈 삽입술의 단기간 임상성적. 대한안과학회지. 2009;50(6):839-851.

이보 ICL의 장점(마치 내 눈 같은 편안함) - 광고심의필: 조합-2022-04-029 (유효기간: 2025.02.03)

1. FDA. Before, During & After Surgery. https://www.fda.gov/medical-de... (as of 2021-12-24). 2. 윤재문 외. 난시교정용 후방 유수정체 안내렌즈 삽입술의 단기간 임상성적. 대한안과학회지. 2009;50(6):839-851.

수술 과정 - 광고심의필: 조합-2022-04-034 (유효기간: 2025.02.03)

1. FDA. Before, During & After Surgery. https://www.fda.gov/medical-de... (as of 2021-12-24) 2. 윤재문 외. 난시교정용 후방 유수정체 안내렌즈 삽입술의 단기간 임상성적. 대한안과학회지. 2009;50(6):839-851. 3. Elena Martines-plaze, et al. Effect of the EVO + Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life. Am J Ophthalmol. 2021;226:117-125. 4. Data on file. STAAR Surgical Annual Report.

자주 묻는 질문 - 광고심의필: 조합-2022-04-035 (유효기간: 2025.02.03)

1. Feingold et al. Biocompatible, optically transparent, ultraviolet light absorbing, polymeric material based upon collagen and method of making. USPTO June 8, 1999. 2. ICL in Treatment of Myopia (ITM) Study Group. Postoperative Inflammation after Implantation of the Implantable Contact Lens. Ophthalmology 2003;110:2335-2341. 3. Risto J. Uusitalo, et al. Implantable contact lens for high myopia. J Cataract Refract Surg 2002(28):29-36. 4. Elena Martines-plaze, et al. Effect of the EVO + Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life. Am J Ophthalmol. 2021;226:117-125.

개인정보 수집 및 이용

이보 ICL 브로슈어 발송을 위한 최소한의 개인정보를 수집하고 이용합니다.

수집된 정보는 이메일 발송 외 다른 목적으로 이용되지 않으며, 서비스가 종료되거나 구독을 해지할 경우 즉시 파기됩니다.